ConductScience.org, home

Paper42907136PubMed

Cell-based therapies for malignant glioma.

Mooney R and 5 others. Stem Cells Transl Med, 2026.

Cite this record

ConductScience Library. Cell-based therapies for malignant glioma. Papers, record 42907136. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42907136

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cell-based therapies for malignant glioma.
Journal
Stem Cells Transl Med
Year
2026
Publication types
Journal Article, Review
Revised in PubMed
2026-11-01

Source PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mooney RRachaelhttps://orcid.org/0000-0002-9069-0206
2Abd El-Fattah EEEslam E
3Ngai GGaryhttps://orcid.org/0000-0001-9444-5200
4Lara JJacqueline
5Hammad MMohamed
6Aboody KSKaren S

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
GliomaMajor topic
Brain NeoplasmsMajor topic
Cell- and Tissue-Based TherapyMajor topic
Humans
Animals
Immunotherapy, Adoptive
Killer Cells, Natural

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Ben & Catherine Ivy FoundationPubMed
CLIN1-14845Rosalinde and Arthur Gilbert Foundation, the Alvarez Charitable Foundation, City of Hope, California Instistute of Regenerative MedicinePubMed
CIRM CLIN2-13162Rosalinde and Arthur Gilbert Foundation, the Alvarez Charitable Foundation, City of Hope, California Instistute of Regenerative MedicinePubMed

Source PubMed

Download CSV of grants

References57

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
140938661Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival.Hum Vaccin Immunother2025https://conductscience.org/library/papers/40938661PubMed
240386781An update on the clinical trial research of immunotherapy for glioblastoma.Front Immunol2025https://conductscience.org/library/papers/40386781PubMed
337148198Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.Neuro Oncol2023https://conductscience.org/library/papers/37148198PubMed
440190555Integrative multi-omic profiling of the neoantigen landscape of glioblastoma for the development of therapeutic vaccines reveals vast heterogeneity in immunogenic signatures.Front Oncol2025https://conductscience.org/library/papers/40190555PubMed
538166251Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy.J Immunol2024https://conductscience.org/library/papers/38166251PubMed
636790010Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know.J Neurosurg2023https://conductscience.org/library/papers/36790010PubMed
734862245A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma.Clin Cancer Res2022https://conductscience.org/library/papers/34862245PubMed
836394838
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
JAMA Oncol2023https://conductscience.org/library/papers/36394838PubMed
928411277Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.Clin Cancer Res2017https://conductscience.org/library/papers/28411277PubMed
1040255400Single-cell and spatial transcriptomic insights into glioma cellular heterogeneity and metabolic adaptations.Front Immunol2025https://conductscience.org/library/papers/40255400PubMed
1137875502Characteristics of premanufacture CD8+T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma.Signal Transduct Target Ther2023https://conductscience.org/library/papers/37875502PubMed
1228426845HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.JAMA Oncol2017https://conductscience.org/library/papers/28426845PubMed
1329093005Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.Cancer Res2018https://conductscience.org/library/papers/29093005PubMed
1432477944Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series.Front Oncol2020https://conductscience.org/library/papers/32477944PubMed
1526873960Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.Clin Cancer Res2016https://conductscience.org/library/papers/26873960PubMed
1635903678Low MxA Expression Predicts Better Immunotherapeutic Outcomes in Glioblastoma Patients Receiving Heat Shock Protein Peptide Complex 96 Vaccination.Front Oncol2022https://conductscience.org/library/papers/35903678PubMed
1732719000Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma.Clin Cancer Res2020https://conductscience.org/library/papers/32719000PubMed
1832750039Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme.J Clin Invest2020https://conductscience.org/library/papers/32750039PubMed
1938042450Radiation Therapy and Myeloid-Derived Suppressor Cells: Breaking Down Their Cancerous Partnership.Int J Radiat Oncol Biol Phys2024https://conductscience.org/library/papers/38042450PubMed
2038454126Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.Nat Med2024https://conductscience.org/library/papers/38454126PubMed

See all 57 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42907136

GET https://conductscience.org/api/papers/v1/42907136/references?page=2